Leerink Partnrs Has Negative Outlook of RVMD FY2025 Earnings

Revolution Medicines, Inc. (NASDAQ:RVMD) – Leerink Partnrs cut their FY2025 earnings estimates for Revolution Medicines in a research report issued on Wednesday, November 5th. Leerink Partnrs analyst J. Chang now forecasts that the company will post earnings of ($5.52) per share for the year, down from their prior forecast of ($5.50). The consensus estimate for Revolution Medicines’ current full-year earnings is ($3.49) per share. Leerink Partnrs also issued estimates for Revolution Medicines’ Q4 2025 earnings at ($1.45) EPS and FY2026 earnings at ($5.05) EPS.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($1.61) EPS for the quarter, missing the consensus estimate of ($1.39) by ($0.22). During the same period in the prior year, the business posted ($0.94) EPS.

RVMD has been the subject of a number of other research reports. National Bankshares set a $80.00 price target on Revolution Medicines in a research report on Friday, October 17th. Truist Financial started coverage on Revolution Medicines in a research note on Friday, September 5th. They issued a “buy” rating and a $99.00 price objective on the stock. Wells Fargo & Company boosted their target price on Revolution Medicines from $67.00 to $70.00 and gave the stock an “overweight” rating in a report on Thursday, September 11th. Lifesci Capital started coverage on Revolution Medicines in a research report on Monday, August 18th. They set an “outperform” rating and a $80.00 target price for the company. Finally, Mizuho started coverage on Revolution Medicines in a report on Tuesday, October 21st. They set an “outperform” rating and a $90.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $78.71.

Revolution Medicines Trading Up 2.2%

Shares of NASDAQ:RVMD opened at $64.08 on Monday. The company has a current ratio of 8.05, a quick ratio of 8.05 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $12.39 billion, a PE ratio of -12.39 and a beta of 1.25. Revolution Medicines has a 1 year low of $29.17 and a 1 year high of $64.26. The firm has a fifty day moving average price of $49.61 and a 200 day moving average price of $42.40.

Insider Buying and Selling

In other news, insider Lin Wei sold 2,160 shares of the firm’s stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $45.82, for a total value of $98,971.20. Following the sale, the insider owned 88,339 shares in the company, valued at approximately $4,047,692.98. This trade represents a 2.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Mark A. Goldsmith sold 13,411 shares of the business’s stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $45.82, for a total transaction of $614,492.02. Following the transaction, the insider owned 452,309 shares in the company, valued at approximately $20,724,798.38. The trade was a 2.88% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 188,033 shares of company stock worth $8,456,208. 8.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Revolution Medicines

Institutional investors have recently added to or reduced their stakes in the company. CWM LLC increased its stake in Revolution Medicines by 171.3% during the second quarter. CWM LLC now owns 917 shares of the company’s stock valued at $34,000 after acquiring an additional 579 shares during the period. GAMMA Investing LLC grew its holdings in shares of Revolution Medicines by 45.1% during the 3rd quarter. GAMMA Investing LLC now owns 837 shares of the company’s stock worth $39,000 after purchasing an additional 260 shares in the last quarter. Banque Transatlantique SA bought a new stake in shares of Revolution Medicines during the first quarter valued at approximately $42,000. Quarry LP bought a new stake in shares of Revolution Medicines during the first quarter valued at approximately $50,000. Finally, Twin Tree Management LP acquired a new position in shares of Revolution Medicines in the first quarter valued at $58,000. 94.34% of the stock is owned by institutional investors and hedge funds.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.